Business Outlook and Planned Value Creating Milestones: The Company estimates revenue in 2023 to be between $25.0 million and $27.0 million, representing growth between 22% and 31%;Submission to the FDA of a Biologics License Application by PTC Therapeutics for Upstaza, using the ClearPoint SmartFlow Cannula, for minimally invasive infusion of the gene therapy; Initiation of multiple pharmaceutical partner clinical trials globally; Expansion of the installed base to approximately 10 additional centers worldwide; Revenue growth from international customers driven by 8 active centers installed in the E.U. and U.K.; Commercialization of the ClearPoint PRISM Neuro Laser Therapy System and expansion into limited market release centers; Completion of Phase 1 safety study in Lund, Sweden, for the use of PRISM to treat brain lesions; Up to 8 FDA submissions for new hardware and software products in our portfolio; Production of first devices at our new expanded manufacturing facility in California.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLPT:
